Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   ARCHIVES OF IRANIAN MEDICINE   MAY 2014 , Volume 17 , Number 5; Page(s) 388 To 390.
 
Paper: 

SUCCESSFUL TREATMENT OF CHRONIC MYELOGENIC LEUKEMIA (CML) WITH IMATINIB AFTER RENAL TRANSPLANTATION

 
DOI: 

0141705/AIM.0015

 
Author(s):  EISHEI OSKUEI ALI, MAKHDOOMI KHADIJEH*, ABKHIZ SAEED, VOSSOGHIAN SARA, FARROKHPOUR MOHSEN
 
* NEPHROLOGY AND KIDNEY TRANSPLANT RESEARCH CENTER, UROMIA, IRAN
 
Abstract: 

Chronic Myelogenic Leukemia (CML) is a rare malignant disorder after solid organ transplantation, especially in renal transplant recipients. Imatinib Mesylate is currently approved as first line treatment of CML. Most reports on CML are from kidney recipients who received azathioprine in combination with cyclosporine and prednisolone as immunosuppressive therapy. We report a case with CML who was treated with Mycophenolate Mofetil.

 
Keyword(s): CHRONIC MYELOGENIC LEUKEMIA, IMATINIB, RENAL TRANSPLANT
 
References: 
  • ندارد
 
  pdf-File tarjomyar Yearly Visit 84
 
Latest on Blog
Enter SID Blog